<DOC>
	<DOCNO>NCT02958111</DOCNO>
	<brief_summary>This randomize , control , multicenter phase 3 clinical trial . The purpose study evaluate efficacy safety single-agent capecitabine adjuvant chemotherapy locoregionally advanced nasopharyngeal carcinoma ( NPC ) .</brief_summary>
	<brief_title>Single-agent Capecitabine Adjuvant Chemotherapy Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>In study , NPC patient ( stage III-IV A , except T3-4 N0 T3 N1 ) finish curative radiotherapy randomize observation group capecitabine group ( 650 mg/m2 bid , p.o.，d1-21，q3wks ; continue disease progression , unacceptable toxicity , 1 year ) . The primary endpoint progression-free survival ( PFS ) . Secondary end point include overall survival ( OS ) , distant failure-free survival ( D-FFS ) , locoregional failure-free survival ( LR-FFS ) , toxic effect , quality life ( QOL ) . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Age 1865 2 . Performance status Eastern Cooperative Oncology Group ( ECOG ) grade 0 1 3 . Tumor stag American Joint Committee Cance ( AJCC ) IIIIV A ( except T34 N0 , T3 N1 ) , newly histologically confirm nonkeratinizing NPC 4 . Within 12 ± 2 week completion recommend curative radiotherapy treatment 5 . No clinical evidence persistent locoregional disease distant metastases radiotherapy 6 . Complete recommend concurrent chemotherapy ± induction chemotherapy 7 . Adequate hematologic ( neutrophil count &gt; 1.5×10^9/L , hemoglobin &gt; 90g/L platelet count &gt; 100×10^9/L ) , hepatic ( alanine aminotransferase , aspartate aminotransferase ≤ 1.5×ULN , bilirubin ≤ 1.5×ULN , alkaline phosphatase &lt; 2.5×ULN ) renal function ( creatinine clearance &gt; 50 ml/min ) 8 . Patients must inform investigational nature study give write informed consent . 1 . Patients could tolerate allergic capecitabine . 2 . Illness would interfere oral medication , include dysphagia , chronic diarrhea , ileus 3 . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . 4 . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . 5 . Patients receive surgery treatment , biotherapy immunotherapy radiotherapy . 6 . Patients receive highly likely receive chemotherapy treatment , biotherapy immunotherapy . 7 . History previous radiotherapy curative radiotherapy ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . 8 . Prior chemotherapy surgery ( except diagnostic ) primary tumor node curative radiotherapy 9 . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Capecitabine</keyword>
</DOC>